Acute Kidney Injury News

Angion Biomedica Corp. has signed a licensing agreement with Vifor Pharma for the commercialization of ANG-3777, a drug shown to treat delayed graft function and cardiac surgery-associated AKI, according to a press release.

Treatment with avacopan can reduce glucocorticoid use, improve disease control, and recover renal function among patients with ANCA-associated vasculitis, according to a speaker at ACR Convergence.

Obinutuzumab provides sustained clinical benefit through 2 years among patients with lupus nephritis, with treatment efficacy maintained 18 months after the final infusion, according to data presented at ACR 2020.

A study conducted by the Feinstein Institutes for Medical Research adds to the growing body of evidence that links AKI to increased mortality risk for patients hospitalized with COVID-19.

A study comparing patients with and those without type 2 diabetes found patients with diabetes had significantly higher rates of AKI than those without the condition.

Patients infected with COVID-19 had a five times greater likelihood of in-hospital mortality if they also developed AKI, according to a study conducted at Tongi Hospital in Wuhan, China.

Young adults who experienced episodes of kidney function decline – termed here as having greater end-stage renal disease risk exposure – had lower cognitive performance at middle age, according to a study published in Neurology.

After assessing AKI in patients with and without COVID-19, researchers from Montefiore Medical Center in New York identified distinct patient characteristics and outcomes associated with the infection.

Study findings indicated use of renin-angiotensin aldosterone inhibitors after AKI did not increase risk for recurrent episodes 1 year after hospital discharge.

The most prevalent comorbidity in patients hospitalized for COVID-19 was hypertension, which was also a risk factor for acute kidney injury in the ED and mortality in these patients, researchers found in two separate studies.